University Of Notre Dame Du Lac Argenx Se Transaction History

University Of Notre Dame Du Lac

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $873,473 - $1.6 Million	-6,854 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $11,100 - $16,853	-102 Reduced 1.47%	6,854 $903,000
Q4 2019 Feb 14, 2020	BUY	$106.59 - $164.21 $37,199 - $57,309	349 Added 5.28%	6,956 $1.12 Million
Q3 2019 Nov 13, 2019	SELL	$113.31 - $150.51 $2.47 Million - $3.28 Million	-21,800 Reduced 76.74%	6,607 $753,000
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $3.27 Million - $4.02 Million	28,407 New	28,407 $4.02 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of University Of Notre Dame Du Lac, based on Form 13F filings with the SEC.

Stay updated on University Of Notre Dame Du Lac with notifications on news.